THE EMERALD CONFERENCE
Produced by MJBizScience

March 1-3, 2023
www.TheEmeraldConference.com

Cytotoxic cannabinoid analogs for prevention of pancreatic cancer

Presenter: Westley Cruces, Chief Science Officer, Colorado Chromatography Labs

Co-Author: Giovanni Ramirez, Kyle Ray, Arianna Collins, Tesfay Tesfatsion

Abstract: Despite recent advances in chemotherapy, pancreatic cancer remains a deadly disease and is the third leading cause of cancer related death within the United States and by 2030, it will be second only to lung cancer. Approximately 62,000 new cases of pancreatic cancer are diagnosed each year within the United States. Pancreatic presents a disturbing fatality rate with more than 49,000 people dying, more than 80% diagnosed will die. Clinical studies on the utility of cannabinoids in the treatment of pancreatic cancer are lacking and are urgently needed. Our group aims to utilize the remarkable properties of rare cannabinoids towards the treatment of cancer and various ailments. The development of antineoplastics for the treatment of pancreatic cancer of less toxic and significantly efficient compounds are unmet and are urgently needed. The IC50 of our modified cannabinoids, CCL-104 and CCL-106 as potential therapeutics for the treatment of pancreatic cancer induced similar or increased cytotoxicity towards pancreatic cancer cell lines compared to the marketed PARP antineoplastic compounds on the market.